Health
Research And Development
Medical

Achillion Pharmaceuticals

$2.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (1.07%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ACHN and other stocks, options, ETFs, and crypto commission-free!

About

Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Read More The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

Employees
56
Headquarters
Blue Bell, Pennsylvania
Founded
1998
Market Cap
393.95M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.69M
High Today
$2.90
Low Today
$2.79
Open Price
$2.82
Volume
939.09K
52 Week High
$3.98
52 Week Low
$1.29

Collections

Health
Research And Development
Medical
Biotechnology
Pharmaceutical
Therapy
Technology
US

News

Yahoo FinanceMay 13

Achillion Reports Wider-Than-Expected Loss in Q1

Achillion Pharmaceuticals, Inc. ACHN incurred a loss of 14 cents per share in the first quarter of 2019, wider than the Zacks Consensus Estimate of a loss of 13 cents. However, it was narrower than the year-ago loss of 15 cents. The company did not generate any revenues in the reported quarter in absence of an approved product in its portfolio. The company’s shares were up 2.5% on May 10 following the earnings release despite the wider-than-expected loss. Shares of Achillion have soared 83% so far this ye...

326
The Motley FoolMay 9

What You Need to Know About Achillion Pharmaceuticals' Q1 Update

245
Yahoo FinanceMay 9

Achillion Reports First Quarter 2019 Financial Results

- PNH combo Phase 2 trial interim data to be presented May 17, 2019 - - C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND submission Q4:2019 - - Cash and securities of $254 million as of March 31, 2019 - BLUE BELL, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today reported its...

13

Earnings

-$0.18
-$0.16
-$0.14
-$0.12
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.